Although blocking either MCT1 or MCT4 may similarly interrupt cell–cell lactate shuttle, the preferential location of MCT1-expressing cancer cells at the vicinity of blood vessels makes MCT1 a more accessible pharmacological target (than MCT4 often located in the far reached hypoxic regions). The gene discussed is SLC16A1; the disease is cancer.